Drug Type CAR-T |
Synonyms- |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD22 modulators(CD22 modulators), T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Orca Biosystems, Inc.Startup |
Active Organization Orca Biosystems, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Phase 1 | US | Orca Biosystems, Inc.Startup | 18 Aug 2022 |
NCT03233854 (Pubmed) Manual | Phase 1 | 38 | CAR T cells with dual targeting of CD19 + CD22 (B-ALL) | ykdumxabap(ukyvizbuhy) = no dose-limiting toxicities occurred during dose escalation pfgfuaobth (oxsytvadht ) | Positive | 01 Aug 2021 | |
CAR T cells with dual targeting of CD19 + CD22 (LBCL) |